MedTrace Logo

mRNA-2736 for Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

NCT05918250 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-08-18

No results posted yet for this study

Summary

This study is designed to evaluate the safety and tolerability of mRNA-2736 in participants with RRMM.

Conditions

Interventions

BIOLOGICAL

mRNA-2736

mRNA-2736 will be administered IV.

Sponsors & Collaborators

  • ModernaTX, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-08-15
Primary Completion
2026-05-27
Completion
2026-05-27
FDA Drug
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05918250 on ClinicalTrials.gov